Jessica K Altman Selected Research

Aligeron (AS 2)

10/2012	Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide.
9/2010	Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide.
5/2010	Arsenic trioxide-dependent activation of thousand-and-one amino acid kinase 2 and transforming growth factor-beta-activated kinase 1.
5/2008	Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2.
1/2008	Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jessica K Altman Research Topics

Disease

40	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 05/2007
15	Neoplasms (Cancer) 01/2022 - 05/2007
15	Leukemia 01/2022 - 01/2008
10	Acute Promyelocytic Leukemia 01/2021 - 05/2007
5	Hematologic Neoplasms (Hematological Malignancy) 01/2020 - 03/2008
5	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 04/2014 - 07/2010
4	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 12/2021 - 05/2015
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021 - 01/2013
2	Hemorrhage 09/2013 - 06/2007
2	Polycythemia Vera 08/2013 - 12/2012
2	Renal Cell Carcinoma (Grawitz Tumor) 05/2012 - 11/2011
2	Leukocytosis (Pleocytosis) 12/2009 - 01/2008
2	Disseminated Intravascular Coagulation 03/2009 - 06/2007
1	Critical Illness (Critically Ill) 04/2022
1	COVID-19 04/2022
1	Abnormal Karyotype 01/2022
1	Anemia 01/2021
1	Pneumonia (Pneumonitis) 01/2021
1	Left Ventricular Dysfunction 11/2019
1	Primary Myelofibrosis (Myelosclerosis) 08/2019
1	Fibrosis (Cirrhosis) 08/2019
1	Splenomegaly 08/2019
1	Histiocytic Sarcoma 03/2019
1	Chromosome Aberrations (Chromosome Abnormalities) 03/2019
1	Residual Neoplasm 01/2018
1	Hyperbilirubinemia 10/2017
1	Fatigue 01/2017
1	Endometrial Neoplasms (Endometrial Cancer) 06/2016
1	Hypersensitivity (Allergy) 01/2016
1	Arthralgia (Joint Pain) 10/2015
1	Arthritis (Polyarthritis) 10/2015
1	Exanthema (Rash) 10/2015

Drug/Important Bio-Agent (IBA)

10	Phosphotransferases (Kinase)IBA 05/2021 - 01/2008
8	Arsenic Trioxide (Trisenox)FDA Link 01/2015 - 01/2008
5	AnthracyclinesIBA 11/2019 - 01/2008
5	TOR Serine-Threonine KinasesIBA 04/2015 - 01/2008
5	Tretinoin (Retinoic Acid)FDA LinkGeneric 06/2014 - 12/2009
5	Proteins (Proteins, Gene)FDA Link 06/2013 - 06/2007
5	Aligeron (AS 2)IBA 10/2012 - 01/2008
4	gilteritinibIBA 01/2022 - 10/2020
4	Mechanistic Target of Rapamycin Complex 2IBA 05/2014 - 07/2010
3	Mitogen-Activated Protein KinasesIBA 01/2022 - 10/2010
3	ivosidenibIBA 11/2021 - 01/2020
3	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2021 - 10/2009
3	Tyrosine Kinase InhibitorsIBA 10/2020 - 11/2013
3	Eukaryotic Initiation Factor-4EIBA 01/2016 - 10/2010
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 12/2013 - 05/2007
3	Small Interfering RNA (siRNA)IBA 08/2013 - 05/2010
3	MTOR InhibitorsIBA 06/2013 - 11/2011
2	Hemoglobins (Hemoglobin)IBA 04/2022 - 01/2021
2	fms-Like Tyrosine Kinase 3IBA 01/2022 - 01/2018
2	Enzyme Inhibitors (Inhibitors, Enzyme)IBA 12/2020 - 05/2015
2	CytokinesIBA 08/2019 - 01/2016
2	ruxolitinibIBA 08/2019 - 01/2014
2	enasidenibIBA 01/2019 - 10/2017
2	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 06/2018 - 10/2017
2	Protein Kinases (Protein Kinase)IBA 01/2016 - 09/2012
2	Peptide Initiation Factors (Initiation Factor)IBA 01/2016 - 10/2010
2	Antineoplastic Agents (Antineoplastics)IBA 04/2015 - 01/2015
2	Mechanistic Target of Rapamycin Complex 1IBA 05/2014 - 07/2011
1	BI 836858IBA 01/2022
1	Sorafenib (BAY 43-9006)FDA Link 01/2022
1	Monoclonal AntibodiesIBA 01/2022
1	midostaurinIBA 01/2022
1	sapacitabineIBA 12/2021
1	tomivosertibIBA 05/2021
1	Lenalidomide (CC 5013)FDA Link 01/2021
1	4-fluorobenzoyl-TN-14003IBA 01/2021
1	Erythropoietin Receptors (Erythropoietin Receptor)IBA 01/2021
1	Erythropoietin FDA Link 01/2021
1	venetoclaxIBA 01/2021
1	Epoetin Alfa (Epogen)FDA Link 01/2021
1	Aurora Kinase AIBA 08/2019
1	MLN 8237IBA 08/2019
1	isocitric acid (isocitrate)IBA 01/2019
1	Arginine (L-Arginine)FDA Link 01/2019
1	quizartinibIBA 01/2018
1	Alanine Transaminase (SGPT)IBA 01/2017
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2017
1	Metformin (Glucophage)FDA LinkGeneric 06/2016
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2016
1	merestinibIBA 01/2016
1	Transcription Factors (Transcription Factor)IBA 01/2016
1	Integrin alphaVbeta3IBA 01/2016
1	IntegrinsIBA 01/2016
1	purineIBA 10/2015
1	Pharmaceutical PreparationsIBA 10/2015
1	VemurafenibIBA 10/2015

Therapy/Procedure

24	Therapeutics 01/2022 - 01/2008
10	Drug Therapy (Chemotherapy) 01/2022 - 01/2008
4	Stem Cell Transplantation 03/2019 - 06/2014
3	Induction Chemotherapy 01/2022 - 11/2019
1	Radiotherapy 01/2022
1	Hematopoietic Stem Cell Transplantation 01/2021
1	Blood Transfusion (Blood Transfusions) 01/2021
1	Precision Medicine 01/2019
1	Intravenous Infusions 01/2018
1	Consolidation Chemotherapy 01/2018
1	Drug Tapering 10/2015
1	Aftercare (After-Treatment) 10/2015